Hi Board. Hope all is well. Just wanted to create this board for people that want to share their thoughts on whats possibly happening with this reorganization and new listing of Immune and it’s subsidiary Cytoviatx.
INDS are being delayed on purpose. You need to look at the IND filing page on latest presentation. They show CHINA IIT in 2023 which is odd as that refers to Chinas new taxation system that is a one time deal that lasts only three years and ends 2025. This taxation dramatically affects new small businesses under 50 million. I believe this will affect our start up CytoLynx and possibly the IND that’s being filed by them.
We could still finalize the combination in 2023 but I think they have other plans. First we must get through that remnant sale which will take us into March 2023. Then we have to wait and see it they decide to use that third year. I think that SPACs use now is to just issue more shares for future financing that will be coming in the fall. Maybe those financings alone will bring Cytoviatx to a public listing as they have said they could do an alternative approach maybe using Isleworth as the broker. CytoLynx will be growing and I think the Chinese are on a mission here. Stay tuned.
Then you have cellectis which we no doubt will have some interest in. Or they’ll have an interest in us. Most likely a majority which will be the sale of the company once they take advantage of the warrants. This is a huge reorganization affecting so many parties. Fun times. Be well. Penny